Medicus Pharma reported an 80% overall response rate (ORR) in Phase 2 data for SkinJect. Dr. Babar Rao, a key opinion leader, validated that the outcomes are clinically meaningful for treating non-melanoma skin cancer. The treatment could potentially allow the majority of lesions to avoid immediate surgery.
PolyPid Ltd. (Nasdaq: PYPD) has officially commenced the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). The application is for D-PLEX₁₀₀, a specialized product designed to prevent surgical site infections (SSIs) in patients undergoing colorectal surgery. This…
Read the full storyIncyte Corporation announced successful 54-week results from its late-stage study of povorcitinib, an oral JAK1 inhibitor. The clinical data demonstrated sustained efficacy in treating patients with Hidradenitis Suppurativa (HS), a chronic inflammatory skin condition. Furthermore, the results reinforced a strong…
Medicus Pharma (MDCX) has announced the successful validation of its Phase 2 clinical trial data for SkinJect, reporting a significant overall response rate (ORR) of 80%. Following the initial report, the company issued formal guidance to clarify the interpretation of the Phase 2 topline dataset. This clarification…